| 000 | 01427 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250514025606.0 | ||
| 264 | 0 | _c20020611 | |
| 008 | 200206s 0 0 eng d | ||
| 022 | _a0901-9928 | ||
| 024 | 7 |
_a10.1034/j.1600-0773.2001.d01-170.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKortunay, S | |
| 245 | 0 | 0 |
_aDose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers. _h[electronic resource] |
| 260 |
_bPharmacology & toxicology _cDec 2001 |
||
| 300 |
_a331-4 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xmetabolism |
| 650 | 0 | 4 | _aCatalysis |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2D6 Inhibitors |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aHistamine H1 Antagonists _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 |
_aPyrilamine _xpharmacology |
| 650 | 0 | 4 |
_aSparteine _xmetabolism |
| 700 | 1 | _aBozkurt, A | |
| 700 | 1 | _aBasci, N E | |
| 700 | 1 | _aBrøsen, K | |
| 700 | 1 | _aKayaalp, S O | |
| 773 | 0 |
_tPharmacology & toxicology _gvol. 89 _gno. 6 _gp. 331-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1034/j.1600-0773.2001.d01-170.x _zAvailable from publisher's website |
| 999 |
_c11809746 _d11809746 |
||